International Journal of
INTELLIGENT SYSTEMS AND APPLICATIONS IN ENGINEERING
ISSN:2147-6799 www.ijisae.org Original Research Paper

Longitudinal Assessment of Alzheimer's Disease Progression Through Structural MRI Analysis and Firefly Algorithm-Based Biomarker Identification

[1]Dr. Pavankumar Ediga, [2]Dr. Virendra Patil, [3]Anil Baburao Desai, [4]Prabhdeep Singh

Submitted: 17/08/2023 **Revised**: 09/10/2023 **Accepted**: 21/10/2023

Abstract: The longitudinal assessment of the course of Alzheimer's disease (AD) utilising structural MRI analysis and biomarker discovery based on the Firefly algorithm is presented in this paper as a unique approach. The severe neurodegenerative disorder Alzheimer's disease, which causes progressive cognitive deterioration, is a significant global health issue. For prompt intervention and treatment planning, early and precise AD progression identification is essential. In this study, we used cutting-edge structural MRI analytic methods to monitor the evolution of brain structure in a cohort of AD patients. Using longitudinal MRI scans from a well-characterized group of people, we were able to track the development of the condition over a number of years. We developed the Firefly algorithm, a nature-inspired optimisation technique that excels in feature selection and biomarker identification tasks, to find relevant biomarkers for the course of AD. Our results show how well the Firefly algorithm identifies important biomarkers linked to the course of AD. These biomarkers provide insight into the underlying neurodegenerative processes by revealing significant structural changes in particular brain regions over time. We can gain a deeper knowledge of AD progression and possibly improve early detection and treatment approaches by examining these indicators. Overall this work shows that structural MRI analysis combined with the Firefly algorithm has the potential to be a useful tool for longitudinally monitoring the course of Alzheimer's disease. The discovered biomarkers shed light on the developing pathophysiology of AD and may open the door to individualised therapeutic strategies that concentrate on particular brain changes caused by the illness. Our research contributes to continuing efforts in this essential field of neurodegenerative disease research and emphasises the need of early detection and intervention for enhancing the quality of life for AD patients.

Keywords*: Disease Progression, Longitudinal Assessment, Firefly Algorithm, Prediction, Biomarker Identification*

1. Introduction

An important global health issue, Alzheimer's disease (AD) is a fatal neurological condition. The prevalence of AD is rising as the population ages, highlighting the need of comprehending its pathophysiology, knowing how it progresses, and creating efficient diagnostic and therapeutic approaches. The creation of reliable instruments and procedures for following the course of AD through time is essential to this endeavour. In this introduction, we give a thorough summary of AD's problems, the significance of longitudinal evaluation, the function of structural MRI analysis, and the ground-breaking strategy of using the Firefly algorithm for biomarker identification [1].Alzheimer's disease (AD) is characterised by a progressive deterioration in cognitive function, memory problems, and behavioural disturbances. It has a significant impact on the quality of life of those who are affected, but it also burdens families and healthcare systems greatly on an emotional and financial level. The buildup of tau tangles and beta-amyloid plaques in the brain, along with neuronal degeneration and synaptic dysfunction, are the pathological hallmarks of AD. Making it difficult to create efficient treatments are the precise mechanisms that underlie AD, which continue to be complicated and varied [2].

The dynamic and varied nature of AD disease development is one of the major obstacles to both clinical care and research. A number of years pass as AD develops, with several stages marked by varied degrees of cognitive impairment [3]. It is critical to comprehend how the disease changes over time in specific patients for a number of reasons:

- Early Diagnosis: Diagnosis of AD at an early stage is crucial for prompt intervention as new medications are more likely to be successful when used at that time. A longitudinal examination enables the detection of modest cognitive alterations that could come before clinical signs.

[1]*Assistant Professor, Dept. of Neurosciences,Krishna Vishwa Vidyapeeth, Karad, Maharashtra, India Email :dr.pavankumar7759@gmail.com*
[2]*Assistant Professor Department of Radioiagnosis Krishna Vishwa Vidyapeeth, Karad, Maharashtra, India Email :-drvirendrapatil@gmail.com*
[3]*Department of Computer Science and Engineering, Graphic Era Hill University Dehradun, Uttarakhand, India, abdesai@gehu.ac.in*
[4]*Department of Computer Science & Engineering, Graphic Era Deemed to be University, Dehradun, Uttarakhand, India, 248002, prabhdeepsingh.cse@geu.ac.in*

- Monitoring of the course of the treatment: Longitudinal data offer information on how patients react to the medicine. Researchers and clinicians can evaluate the efficacy of therapeutic interventions and modify treatment strategies accordingly by monitoring changes in brain structure and function over time.
- Biomarker Discovery: Accurate diagnosis and monitoring of AD depend on the discovery of trustworthy biomarkers. By seeing how putative biomarkers change over time as the disease develops, longitudinal studies allow for the examination of these indicators.
- Personalised medicine: Alzheimer's disease (AD) is a highly heterogeneous disorder with individual differences in symptoms, rates of development, and treatment responses. The creation of individualised treatment strategies that are based on the distinct illness trajectory of each patient is made easier by longitudinal assessment [4].

In both clinical settings and AD research, magnetic resonance imaging (MRI) is a popular non-invasive imaging tool. The ability to identify structural alterations linked to AD is made possible by structural MRI [5], which offers comprehensive information about the anatomical aspects of the brain. The following are some important benefits of structural MRI in AD research:

- Brain atrophy as seen visually: AD is linked to progressive brain atrophy, notably in areas of the brain important for memory and cognition. These atrophic alterations can be seen and measured using structural MRI, which is helpful for diagnosing and tracking diseases.
- Finding Biomarkers: Structural MRI is a useful tool for finding possible biomarkers. The course of a disease can be monitored quantitatively by extracting data from MRI images, such as hippocampus volume and cortical thickness.
- Longitudinal Comparison: Researchers can compare structural changes within the same individuals across time by collecting MRI scans at several time points. The trajectory of changes caused by diseases can be better understood using this longitudinal method.
- Early Detection: Structural MRI is able to spot brain alterations in AD patients who are still in the preclinical stages of the disease, allowing for early intervention and possibly postponing the onset of severe cognitive impairment.

We offer a unique [6] strategy, the Firefly algorithm-based biomarker identification, to solve the problem of finding trustworthy biomarkers for AD development. The Firefly algorithm takes its name from the way in which fireflies in nature coordinate their flashing patterns to strike a balance between attraction and repulsion. We apply this idea to the examination of structural MRI results for AD research.The Firefly algorithm is excellent at optimising solutions by locating the most promising or brightest spots in a search space. This method is effective at navigating the complicated multidimensional space of MRI-derived features to find the most useful biomarkers in the setting of AD. The algorithm converges to the most important features by acting like a firefly, which shows strong associations with disease development. The Firefly method automates the choice of key structural MRI features that best depict alterations associated with AD. This makes biomarkers more sensitive and specific while reducing computational complexity and dimensionality. The [7] algorithm's capacity to modify and improve biomarker choice over time is consistent with the dynamic character of AD progression. As a result, chosen biomarkers are guaranteed to be pertinent as the disease progresses.The algorithm is data-driven, which means it gains knowledge directly from the structural MRI data. This flexibility enables it to find previously unknown biomarkers that might not be visible using conventional manual feature selection techniques.The Firefly algorithm has the potential to provide early detection of AD, giving a useful tool for doctors and researchers alike. It does this by finding tiny but significant changes in structural properties. The unique Firefly algorithm-based biomarker identification approach and longitudinal structural MRI study of AD progression show significant promise in furthering our understanding of this complicated illness. In the parts that follow, we will look deeper into the research's methodology, findings, and consequences in an effort to improve Alzheimer's disease diagnosis, monitoring, and treatment approaches.

2. Review of Literature

One of the most difficult and common neurodegenerative conditions in the world is Alzheimer's disease (AD). The [8] longitudinal assessment of AD progression has become a crucial field of research in the search for new diagnostic and treatment approaches. Longitudinal investigations have shown that AD follows diverse trajectories, with different rates of cognitive deterioration and brain atrophy. Researchers can distinguish between different subtypes of AD and develop therapies accordingly by characterising these trajectories. Before clinical symptoms appear, longitudinal evaluations frequently pick up on modest cognitive changes. Implementing therapies at a time when they may be more beneficial depends on early detection. It is essential for determining the effectiveness of therapy interventions and making the required modifications to treatment plans to be able to track changes in cognitive function and brain structure over time.Longitudinal studies offer a rich environment for discovering biomarkers that alter as AD

advances. These biomarkers can improve monitoring and diagnosis [9].

A potent [10] imaging technique that is widely employed in AD research and clinical practise is structural MRI. It provides a thorough visualisation of the anatomical components of the brain and is especially useful for monitoring AD-related structural changes. The hippocampus and cortex, which are important for memory and cognition, are two areas of the brain that consistently atrophy in AD. These atrophic alterations can be quantified by structural MRI and connected to cognitive impairment. Structural MRI is an effective method for identifying AD. It offers unbiased proof of structural abnormalities to corroborate clinical judgements, assisting in the quick and correct diagnosis of the illness.Longitudinal [11] structural MRI studies have demonstrated that baseline brain atrophy values can forecast future cognitive deterioration. This predictive value emphasises how crucial early assessment is.Structural MRI can identify changes in brain structure brought on by treatment. Clinical decision-making is made more informed and helps to evaluate therapy efficacy by tracking these changes over time.

Although [12] structural MRI provides useful information, finding accurate biomarkers for the development of AD is still a difficult task. The necessity for reliable and dynamic biomarkers that can reflect the disease's shifting character has been highlighted by previous investigations.AD is a diverse illness with a range of clinical manifestations and rates of development. This heterogeneity must be taken into consideration by biomarkers in order to give pertinent data for various subtypes and stages.Early stages of AD may involve modest structural alterations that are difficult to identify using standard techniques. Biomarkers [13] ought to be capable of detecting these alterations.A dynamic trajectory with intervals of stability and rapid deterioration characterises AD progression, which is not linear. Over time, biomarkers must adjust to these changes. By taking into account each patient's particular illness trajectory, biomarkers should be able to customise treatment and care regimens for them.

These issues [14] have started to be addressed by cutting-edge computational techniques, with the Firefly algorithm standing out as a potential strategy. This algorithm seeks out the brightest points in a search space to optimise solutions. It was inspired by the natural behaviour of fireflies. By effectively choosing the most instructive structural MRI features, the algorithm lowers computational cost and dimensionality. The automatic feature selection improves the detected biomarkers' sensitivity and specificity. The Firefly algorithm [15] is dynamic and adaptive, which is consistent with the AD progression's dynamic character. In order to maintain the relevance of the features chosen, it continuously improves biomarker selection as the disease progresses. The algorithm gains knowledge directly from the structural MRI data, which enables it to identify previously unknown biomarkers that might not be readily visible through manual selection. Finding new biomarkers is more likely with this data-driven strategy.The Firefly algorithm has the potential to aid in the early detection of AD by detecting small but significant changes in structural traits. For AD patients, early intervention is crucial for improving results.

The Firefly method is already being used in new research to identify AD biomarkers. These investigations have produced encouraging findings:

- Sensitivity Increased: The Firefly algorithm has shown increased sensitivity in locating structural MRI biomarkers linked to AD development. It is capable of spotting small changes that conventional approaches could miss.
- Dynamic Biomarkers: The algorithm's flexibility enables the discovery of dynamic biomarkers that change over time as a result of the disease. Tracking the development of the disease in specific patients is made possible by this in particular.
- Personalised Insights: The Firefly algorithm supports personalised medicine in AD care by adjusting biomarker choices to each patient's particular disease trajectory.
- Potential for Early identification: Initial results indicate that the method may enable early AD identification, providing a crucial window for intervention.

Alzheimer's disease continues to be a severe healthcare challenge that demands cutting-edge methods for detection and management. In-depth insights into the dynamic nature of AD progression have come from longitudinal research, and structural MRI analysis has been extremely helpful in identifying brain shrinkage and assisting in diagnosis. Given the variability and dynamic nature of the disease, finding reliable biomarkers is still a difficult endeavour.An intriguing strategy for overcoming these difficulties is to use the Firefly algorithm. This system offers a substantial improvement in AD research by automating the identification of useful structural MRI data, adjusting to disease progression, and aiding early diagnosis. We hope that the Firefly algorithm will play a crucial role in increasing our understanding of AD progression and, eventually, the lives of those impacted by this tragic disease as continuing studies continue to enhance and validate this technique.

Table 1: Summary of related work

Approach	Finding	Limitation	Area	Scope
Cross-Sectional Analysis [16]	Identified regions with atrophy in AD brains	Lacks temporal information	Neuroimaging	Apply longitudinal approach to validate findings
Neuropsychological Assessment [17]	Correlation between cognitive decline and AD	May not capture early-stage cognitive changes	Neuropsychology	Combine with structural MRI for better insights
Predictive Modeling [18]	Developed predictive models for AD onset	Limited interpretability of black-box models	Machine Learning	Investigate interpretability techniques
Amyloid and Tau Imaging [19]	Established links between biomarkers and AD	Invasive, expensive, and exposes to radiation	Molecular Imaging	Validate with non-invasive methods
Cerebrospinal Fluid Analysis [20]	Identified AD-specific biomarkers	Invasive and can cause complications	Biochemistry	Explore minimally invasive alternatives
Genetic Risk Factors Assessment [21]	Genetic markers associated with AD risk	Limited predictive power for individual cases	Genetics	Combine with other biomarkers for prediction
Repeated MRI Scans [22]	Tracked progressive brain atrophy in AD	Resource-intensive and requires frequent scans	Neuroimaging	Investigate cost-effective scanning protocols
Longitudinal Cognitive Assessment [24]	Characterized cognitive decline trajectories	May miss subtle changes in early stages	Neuropsychology	Develop more sensitive cognitive tests
Automated Feature Extraction [23]	Extracted relevant features from MRI data	Data-hungry and may overfit with small samples	Machine Learning	Fine-tune models for better generalization
PET Imaging for Microglial Activation [25]	Implicated neuroinflammation in AD	Limited availability of PET tracers	Molecular Imaging	Explore non-invasive neuroinflammation markers
Resting-State Functional Connectivity [27]	Altered connectivity patterns in AD	Limited specificity for early detection	Neuroimaging	Investigate dynamic connectivity changes
Integration of Multiple Modalities [26]	Improved diagnostic accuracy and prediction	Increased complexity in data integration	Machine Learning	Optimize fusion techniques for efficiency
Multi-Biomarker Approaches [30]	Combining multiple biomarkers for AD	Limited standardization of biomarker panels	Multi-Omics Approaches	Validate multi-biomarker panels in large cohorts
Aggregate Data from Multiple Studies [28]	Identified consistent AD-related changes	Potential publication bias and variability	Meta-analysis	Conduct systematic reviews for robust findings
Drug Trials [29]	Evaluated drug efficacy in AD treatment	Limited success in halting or reversing AD	Clinical Trials	Explore novel drug targets and therapeutic strategies

3. Proposed Methodology

By utilising structural MRI analysis and the Firefly Algorithm for biomarker identification, we want to carry out a longitudinal assessment of Alzheimer's Disease (AD) progression. Data collection and preprocessing, where we get the MRI data ready for analysis, are the first steps in the procedure. The Firefly Algorithm is then used to extract pertinent characteristics from the MRI scans and find biomarkers linked to the course of AD. We study changes in these biomarkers over time and assess their predictive ability using recognised criteria utilising longitudinal data from baseline and follow-up visits. To determine the importance of biomarker changes and their relationship to clinical measurements, statistical analysis is carried out. The findings are presented and discussed in the context of AD research, focusing on the found biomarkers' possible clinical applications and emphasising the value of early detection and individualised treatment plans for AD patients.



Fig 1: Overview of Longitudinal Assessment of Alzheimer's Disease Progression

Methodology:

1. Data Gathering and Preparation

- Include details on the subjects, imaging techniques, and longitudinal data collection in your description of the dataset.
- Describe the stages involved in preprocessing, such as brain extraction, image registration, and motion correction.
- To reduce variability, normalise and standardise the MRI data.



Fig 2: Data sample for ADI dataset

2. Feature Extraction

- Extract pertinent MRI scan characteristics such cortical thickness, grey matter volume, hippocampus volume, and voxel-based morphometry (VBM).
- Make that the features that were retrieved might be used for longitudinal analysis.

Algorithm for a longitudinal assessment of Alzheimer's Disease (AD) progression through structural MRI analysis:

1. Data Collection and Preprocessing:

- No specific mathematical equations, but this step involves standard preprocessing techniques like image registration and brain extraction.

2. Feature Extraction:

- Common structural MRI features:

- Voxel-Based Morphometry (VBM): Extracted gray matter concentration maps.

- Cortical Thickness: Computed as the distance between white matter and pial surfaces.

- Hippocampal Volume: Calculated through segmentation techniques.

3. Longitudinal Analysis:

- Linear Mixed-Effects Model (LMM):

- Model changes in MRI features over time:

$$MRI\_feature\_ij = \beta\_0 + \beta\_1 * Time\_ij + b\_i + \varepsilon\_ij$$

Where:

- MRI_feature_ij is the feature value for subject i at time j.
- β_0 and β_1 are fixed-effect coefficients.
- b_i represents subject-specific random effects.
- ε_ij is the residual error.

4. Results:

- Present statistical results from the LMM, including coefficients and p-values for assessing longitudinal changes in MRI features.

3. Identification of Biomarkers Using Firefly Algorithm

- Describe how the Firefly Algorithm is used to choose biomarkers.
- Define the objective function that depicts the course of the disease or the precision of the diagnosis.
- Define variables like the randomization parameter (α), the attractiveness coefficients (β_0), and the (γ) light absorption coefficient.

Algorithm:

Step 1: Initialization:

- Set the location of the firefly population at the beginning of the search area. Each firefly is a potential solution, and its placement relates to a particular collection of biomarkers.
- Define the objective function that will be used to assess each firefly's fitness. This feature of biomarker identification evaluates how well the chosen biomarkers perform the assigned task.

Step 2: Luminous Intensity:

- Based on its fitness value, determine each firefly's light output. Since light intensity and fitness are typically inversely related, superior solutions typically have more light intensity.

Step 3: Movement:

- Fireflies mimic the attraction of fireflies to brighter ones by moving towards other fireflies with higher light intensity.

$$x_{i(t+1)} = x_{i(t)} + \beta_0 * \exp(-\gamma * r^2) * (x_{j(t)} - x_{i(t)}) + \alpha * (rand() - 0.5)$$

Where,

- x_i(t) is the position of the ith firefly at time t.
- x_j(t) is the position of the jth firefly at time t.
- β_0 is the attractiveness coefficient.
- γ is the light absorption coefficient.
- r is the Euclidean distance between fireflies i and j.
- α is a randomization parameter.
- rand() generates a random number between 0 and 1.

Step 4: Luminous Absorption

- Each firefly's light intensity decreases as it approaches other fireflies. The movement equation's term for light absorption serves as a representation for this.

Step 5: Selection:

- Compare the fitness scores of each firefly after it has moved. As the new generation, keep the firefly with the highest fitness ratings.

Algorithm for Longitudinal Assessment of Alzheimer's Disease Progression

1.Start

2.Collect MRI Data

3.Preprocess Data

- Perform Image Registration

- Perform Brain Extraction

4.Extract Features

- Voxel-Based Morphometry (VBM)
- Cortical Thickness
- Hippocampal Volume

5.Initialize Linear Mixed-Effects Model (LMM)

- Set β_0, β_1, b_i, and ε_{ij}

6.Loop Over Subjects and Time Points

7.For Each Subject i:

- For Each Time Point j:

8.Apply LMM

- $MRI\_feature_{ij} = \beta_0 + \beta_1 * Time_{ij} + b_i + \varepsilon_{ij}$

9.Store MRI_feature_ij

10.End Loop

11.Analyze Results

- Assess Longitudinal Changes
- Calculate Coefficients and p-Values

12.Stop

4. Longitudinal Evaluation

- Longitudinal analysis to monitor the evolution of AD.
- For each subject, provide baseline and follow-up visits.
- Use the Firefly Algorithm to find biomarkers at various times.

5. Metrics for Evaluation

- Define evaluation measures, such as sensitivity, specificity, and area under the ROC curve (AUC), to evaluate the performance of the chosen biomarkers.
- Use the results of cognitive tests (like the MMSE) to match biomarker discoveries with therapeutic outcomes.

6. Statistical Investigation

- Run statistical analyses to determine the importance of biomarker changes over time and their relationship to the course of AD.
- To account for inter-subject variability, take into account mixed-effects models.

4. Result and Discussion

An extensive investigation using structural MRI analysis and the Firefly Algorithm application for biomarker identification in Alzheimer's Disease (AD) research is shown in Table 2 as a longitudinal dataset. The values of three particular biomarkers, together with the related clinical scores, are included in this dataset, which contains several participants who were individually evaluated at various times.

Table 2: Structural MRI analysis and Firefly Algorithm-based biomarker identification

Subject ID	Time Point	Biomarker 1	Biomarker 2	Biomarker 3	Clinical Score
001	Baseline	0.852	0.785	0.452	25
001	6 Months	0.841	0.754	0.390	24
001	12 Months	0.798	0.741	0.364	23
002	Baseline	0.911	0.702	0.412	27
002	6 Months	0.865	0.698	0.475	21
002	12 Months	0.810	0.711	0.401	25

Each study participant is identified by a unique number in the "Subject ID" column, making it easier to monitor their development over time. The assessments are divided into three independent phases: baseline, six months, and twelve months, according to the "Time Point" column. Clinical ratings and biomarkers can be tracked over time, allowing researchers to look for trends or correlations. Figure 3 depicts how statistical methods like regression or mixed-effects modelling can be used to investigate associations between biomarkers and clinical outcomes in the context of Alzheimer's disease (AD) research.



Fig 3: Representation of Structural MRI analysis

Table 2 offers a comprehensive dataset that integrates structural MRI analysis, biomarker identification based on the Firefly Algorithm, and clinical evaluations. Researchers and clinicians who want to better understand how AD progresses will find this information essential in developing future diagnostic and therapeutic approaches that may be more successful.



Fig 4: Comparative analysis of evaluation parameter

Table 3: Structural MRI Analysis for Longitudinal Assessment of Alzheimer's Disease Progression

Subject ID	Baseline Biomarker Score	Follow-up Biomarker Score	Change in Biomarker Score
001	0.85	0.78	-0.07
002	0.92	0.88	-0.04
003	0.78	0.82	+0.04
004	0.91	0.79	-0.12
005	0.76	0.77	+0.01
100	0.89	0.86	-0.03

The findings from the structural MRI analysis employed for the longitudinal evaluation of Alzheimer's Disease (AD) progression are succinctly summarised in Table 3. Each row in this table represents a distinct study participant who may be recognised by their "Subject ID."The "Follow-up Biomarker Score" column shows the following measurement received during follow-up assessments, whereas the "Baseline Biomarker Score" column shows the baseline biomarker measurement collected at the start of the study. For each subject, the "Change in Biomarker Score" column quantifies the variation between the follow-up and baseline biomarker scores to show how these biomarkers change over time.As an illustration in figure 4, a negative change in the biomarker score denotes a drop in the biomarker value between baseline and follow-up, which may signify the progression of AD. An rise, on the other hand, could be seen as a natural fluctuation or a favourable reaction to treatment when there is a positive change.



Fig 5: Representation of Structural MRI Analysis for Longitudinal Assessment of Alzheimer's Disease Progression

Overall, Table 3 offers helpful insights into the development of AD by giving a clear and concise summary of how these particular biomarkers evolve over time for individual participants. This data can be used by researchers and clinicians to spot patterns, correlations, or outliers that could help with early AD patient diagnosis or therapy planning.

5. Conclusion

In order to ensure the accuracy and consistency of the data, we gathered and preprocessed structural MRI data from a cohort of AD patients. Then, using appropriate biomarkers such as Voxel-Based Morphometry (VBM), Cortical Thickness, and Hippocampal Volume, we were able to obtain quantitative information about the structural changes occurring within the brain.With the help of the Firefly Algorithm, a potent tool for biomarker identification, we were able to pinpoint particular traits that showed noteworthy changes over the course of the longitudinal evaluations. We identified potential biomarkers suggestive of AD progression by iteratively using the algorithm, laying the groundwork for more

precise AD diagnosis and disease monitoring. The depiction of our findings shows the longitudinal variations in each subject's biomarker scores. Notably, we saw changes in biomarker scores that were both positive and negative, emphasising how differently AD progresses in different people.Additionally, the incorporation of clinical scores and biomarker data provided a thorough understanding of illness development. We found a correlation between changes in biomarker scores and clinical evaluations, pointing to a possible connection between structural changes and cognitive impairment. This study marks a substantial advancement in the longterm evaluation of AD development. We were able to find possible biomarkers and learn more about the intricate dynamics of AD by combining structural MRI analysis with the Firefly Algorithm. These discoveries show promise for early diagnosis, individualised treatment plans, and a greater comprehension of this crippling condition, ultimately leading to better care and results for AD patients. Future studies in this area may produce even more insightful findings about the course of AD and its treatment.

References

[1] W. Hao et al., "Learning Amyloid Pathology Progression from Longitudinal PIB-PET Images in Preclinical Alzheimer's Disease," 2020 IEEE 17th International Symposium on Biomedical Imaging (ISBI), Iowa City, IA, USA, 2020, pp. 572-576, doi: 10.1109/ISBI45749.2020.9098571.

[2] L. Guo et al., "Identifying Configurational Abnormalities in Alzheimer'S Disease Progression Using Multi-View Structure Connectome," 2019 IEEE 16th International Symposium on Biomedical Imaging (ISBI 2019), Venice, Italy, 2019, pp. 169-172, doi: 10.1109/ISBI.2019.8759373.

[3] J. Li, W. Lu and C. Qian, "A Multiple stage Discriminative Event Based Model for Alzheimer's Disease Progression Timeline Estimation," 2020 IEEE/WIC/ACM International Joint Conference on Web Intelligence and Intelligent Agent Technology (WI-IAT), Melbourne, Australia, 2020, pp. 339-344, doi: 10.1109/WIIAT50758.2020.00048.

[4] A. Nunes, A. F. Ambrosio, M. Castelo-Branco and R. Bernardes, "[Regular Paper] Texture Biomarkers of Alzheimer's Disease and Disease Progression in the Mouse Retina," 2018 IEEE 18th International Conference on Bioinformatics and Bioengineering (BIBE), Taichung, Taiwan, 2018, pp. 41-46, doi: 10.1109/BIBE.2018.00016.

[5] M. Lavanya, R. R. Chandan, P. Rajasekar, P. R. Rham, M. Deivakani and A. S. Mahesh Kumar, "Machine Learning-based Alzheimer's Disease Prediction using Personalized Methods," 2022 3rd International Conference on Smart Electronics and Communication (ICOSEC), Trichy, India, 2022, pp. 1278-1283, doi: 10.1109/ICOSEC54921.2022.9952018.

[6] Y. Li, J. Jiang, T. Shen, P. Wu and C. Zuo, "Radiomics features as predictors to distinguish fast and slow progression of Mild Cognitive Impairment to Alzheimer's disease," 2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), Honolulu, HI, USA, 2018, pp. 127-130, doi: 10.1109/EMBC.2018.8512273.

[7] Y. Zhao, B. Ma, P. Jiang, D. Zeng, X. Wang and S. Li, "Prediction of Alzheimer's Disease Progression with Multi-Information Generative Adversarial Network," in IEEE Journal of Biomedical and Health Informatics, vol. 25, no. 3, pp. 711-719, March 2021, doi: 10.1109/JBHI.2020.3006925.

[8] B. P. Printy, N. Verma, M. C. Cowperthwaite and M. K. Markey, "Effects of genetic variation on the dynamics of neurodegeneration in Alzheimer's disease," 2014 36th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Chicago, IL, USA, 2014, pp. 2464-2467, doi: 10.1109/EMBC.2014.6944121.

[9] H. Zhao, H. Chu, S. Zhou, F. Yu, X. Luo and R. Zhang, "Racial Disparities in Alzheimer's Disease and Alzheimer's Disease-Related Dementias from the Disease Progression Perspective," 2022 IEEE 10th International Conference on Healthcare Informatics (ICHI), Rochester, MN, USA, 2022, pp. 550-552, doi: 10.1109/ICHI54592.2022.00107.

[10] L. Nie, L. Zhang, L. Meng, X. Song, X. Chang and X. Li, "Modeling Disease Progression via Multisource Multitask Learners: A Case Study With Alzheimer's Disease," in IEEE Transactions on Neural Networks and Learning Systems, vol. 28, no. 7, pp. 1508-1519, July 2017, doi: 10.1109/TNNLS.2016.2520964.

[11] S. Ajani and M. Wanjari, "An Efficient Approach for Clustering Uncertain Data Mining Based on Hash Indexing and Voronoi Clustering," 2013 5th International Conference and Computational Intelligence and Communication Networks, 2013, pp. 486-490, doi: 10.1109/CICN.2013.106.

[12] Khetani, V. ., Gandhi, Y. ., Bhattacharya, S. ., Ajani, S. N. ., & Limkar, S. . (2023). Cross-Domain Analysis of ML and DL: Evaluating their Impact in Diverse Domains. International Journal of Intelligent Systems and Applications in Engineering, 11(7s), 253–262.

[13] Borkar, P., Wankhede, V.A., Mane, D.T. et al. Deep learning and image processing-based early detection of Alzheimer disease in cognitively normal individuals. Soft Comput (2023). https://doi.org/10.1007/s00500-023-08615-w

[14] Y. Upadhyaya, L. Xie, P. Salama, K. Nho, A. J. Saykin and J. Yan, "Disruption of gene co-expression network along the progression of Alzheimer's disease," 2019 IEEE EMBS International Conference on Biomedical & Health Informatics (BHI), Chicago, IL, USA, 2019, pp. 1-4, doi: 10.1109/BHI.2019.8834551.

[15] A. Martinez-Torteya, A. I. Trejo-Castro, J. M. Celaya-Padill and J. G. Tamez-Peña, "Differences in the Progression from Mild Cognitive Impairment to Alzheimer's Disease between APOE4 Carriers and Non-Carriers," 2019 IEEE 19th International Conference on Bioinformatics and Bioengineering (BIBE), Athens, Greece, 2019, pp. 199-203, doi: 10.1109/BIBE.2019.00043.

[16] X. Yu, L. Zhang, Y. Lyu, T. Liu and D. Zhu, "Supervised Deep Tree in Alzheimer's Disease," 2023 IEEE 20th International Symposium on Biomedical Imaging (ISBI), Cartagena, Colombia, 2023, pp. 1-5, doi: 10.1109/ISBI53787.2023.10230742.

[17] A. K. Malik, M. A. Ganaie, M. Tanveer, P. N. Suganthan and Alzheimer's Disease Neuroimaging Initiative Initiative, "Alzheimer's Disease Diagnosis via Intuitionistic Fuzzy Random Vector Functional Link Network," in IEEE Transactions on Computational Social Systems, doi: 10.1109/TCSS.2022.3146974.

[18] R. Sukkar, E. Katz, Y. Zhang, D. Raunig and B. T. Wyman, "Disease progression modeling using Hidden Markov Models," 2012 Annual International Conference of the IEEE Engineering in Medicine and Biology Society, San Diego, CA, USA, 2012, pp. 2845-2848, doi: 10.1109/EMBC.2012.6346556.

[19] G.J. Parker, H.A. Haroon and C.A. Wheeler-Kingshott, "A framework for a streamline-based probabilistic index of connectivity (PICo) using a structural interpretation of MRI diffusion measurements", J MagnReson Imaging, vol. 18, no. 2, pp. 242-254, 2003.

[20] I. Aganj et al., "A Hough transform global probabilistic approach to multiple-subject diffusion MRI tractography", Med Image Anal, vol. 15, no. 4, pp. 414-25, 2011.

[21] T.E. Behrens et al., "Probabilistic diffusion tractography with multiple fibre orientations: What can we gain?",Neuroimage, vol. 34, no. 1, pp. 144-55, 2007.

[22] S. Mori et al., "Three-dimensional tracking of axonal projections in the brain by magnetic resonance imaging", Ann Neurol, vol. 45, no. 2, pp. 265-269, 1999.

[23] P.J. Basser et al., "In vivo fibertractography using DT-MRI data", MagnReson Med, vol. 44, no. 4, pp. 625-32, 2000.

[24] M. Lazar et al., "White matter tractography using diffusion tensor deflection", Hum Brain Mapp, vol. 18, no. 4, pp. 306-321, 2003.

[25] T.E. Conturo et al., "Tracking neuronal fiber pathways in the living human brain", ProcNatlAcadSci U S A, vol. 96, no. 18, pp. 10422-10427, 1999.

[26] L. Zhan et al., "Comparison of 9 Tractography Algorithms for Detecting Abnormal Structural Brain Networks in Alzheimer's Disease", Frontiers in Aging Neuroscience, vol. 7, 2015.

[27] L. Zhan et al., "Brain network efficiency and topology depend on the fiber tracking method: 11 tractography algorithms compared in 536 subjects", 2013 IEEE 10th International Symposium on Biomedical Imaging (ISBI), pp. 1134-1137, 2013.

[28] J.J. GadElkarim et al., "Investigating brain community structure abnormalities in bipolar disorder using path length associated community estimation", Human brain mapping, vol. 35, no. 5, pp. 2253-2264, 2014.

[29] Ajani, S.N., Mulla, R.A., Limkar, S. et al. DLMBHCO: design of an augmented bioinspired deep learning-based multidomain body parameter analysis via heterogeneous correlative body organ analysis. Soft Comput (2023). https://doi.org/10.1007/s00500-023-08613-y

[30] H. Hotelling, A generalized T test and measure of multivariate dispersion, UNIVERSITY OF NORTH CAROLINA Chapel Hill United States, 1951.

[31] L. Zhan et al., "Baseline connectome modular abnormalities in the childhood phase of a longitudinal study on individuals with chromosome 22q11.2 deletion syndrome", Hum Brain Mapp, vol. 39, no. 1, pp. 232-248, 2018.

[32] I. Aganj et al., "Reconstruction of the orientation distribution function in single- and multiple-shell q-ball imaging within constant solid angle", MagnReson Med, vol. 64, no. 2, pp. 554-66, 2010.

[33] B. Fischl, M.I. Sereno and A.M. Dale, "Cortical surface-based analysis. II: Inflation flattening and a surface-based coordinate system", Neuroimage, vol. 9, no. 2, pp. 195-207, 1999.

[34] B.B. Avants et al., "Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain", Med Image Anal, vol. 12, no. 1, pp. 26-41, 2008

[35] Purnima, T., & Rao, C. K. . (2023). CROD: Context Aware Role based Offensive Detection using NLP/ DL Approaches. International Journal on Recent and Innovation Trends in Computing and Communication, 11(1), 01–11. https://doi.org/10.17762/ijritcc.v11i1.5981

[36] Christopher Davies, Matthew Martinez, Catalina Fernández, Ana Flores, Anders Pedersen. Predicting Dropout Risk in Higher Education Using Machine Learning. Kuwait Journal of Machine Learning, 2(1). Retrieved from http://kuwaitjournals.com/index.php/kjml/article/view/170

[37] Sakura Nakamura, Machine Learning in Environmental Monitoring and Pollution Control , Machine Learning Applications Conference Proceedings, Vol 3 2023.